Latest Content

Psychiatrists unpack parental leave anxiety, FMLA gaps, and how smarter time-off planning can reduce postpartum depression and support working families.

Phase 3 data show COMP360 psilocybin delivers rapid, lasting relief in treatment-resistant depression; FDA filing advances toward 2027 launch.

Open-label phase 2 trial tests IV Briumvi alongside antipsychotics for treatment-resistant schizophrenia, targeting B-cell depletion to improve symptoms and assess safety.

Share insights on substance use care—practice tips, research, and cases—for Psychiatric Times’ July 2026 series. Pitch your article today.

ASCP panel offers deprescribing guidance to curb psychiatric overprescribing, simplify polypharmacy, and improve outcomes with tapering and

Psychiatrists debunk 10 common antidepressant myths—placebo claims, addiction fears, suicide risk, overuse, and withdrawal—offering evidence-based guidance.

In the first ever episode of "On Your Mind With Erin Crown," explore how tribalism hurts the field of psychiatry and ultimately patient outcomes.

Phase 3b trial shows centanafadine eases adult ADHD and anxiety symptoms fast, with expected safety profile, as FDA review nears.

AI may assist psychopharmacology by aiding suicide risk, digital phenotyping, and TRD care—while exposing EHR data limits and the need for smarter integration.

Check out the pipeline updates from June!

Largest real-world analysis shows Deep TMS cuts PTSD and depression symptoms in comorbid patients; promising but not FDA-cleared yet.

David Dunner, MD, FACPsych, reveals insights into rapid cycling roots, bipolar II, and weighing lithium as an often overlooked treatment option.

Transgender psychiatrists of color share APA first-panel insights on identity, allyship, and gender-affirming care—urging intersectional, culturally engaged mental health practice.